Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Diagnostics Lab, |
RCV003236772 | SCV003935927 | likely pathogenic | 3-Methylglutaconic aciduria type 2 | 2021-04-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003236772 | SCV004299705 | uncertain significance | 3-Methylglutaconic aciduria type 2 | 2024-08-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln275*) in the TAZ gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 18 amino acid(s) of the TAZ protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of TAZ-related conditions (PMID: 33500567; external communication). ClinVar contains an entry for this variant (Variation ID: 42269). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Laboratory for Molecular Medicine, |
RCV000035102 | SCV000058742 | likely pathogenic | Primary dilated cardiomyopathy | 2008-04-24 | no assertion criteria provided | clinical testing |